FDA REFORM BILL SHOULD ENFORCE GENERIC SUBSTITUTION RATINGS, MYLAN VP TELLS HOUSE SUBCOMMITTEE; GENERIC DRUG INDUSTRY SEEKS INCLUSION IN REFORM PROVISIONS
Executive Summary
FDA reform legislation should pre-empt state substitution decisions for "AB"-rated generics, Mylan Pharmaceuticals VP and General Counsel Roger Foster told the House Commerce/Health Subcommittee May 2.